Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

GVAX vs. Placebo for MDS/AML After Allo HSCT

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Vincent T. Ho, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01773395
First received: January 8, 2013
Last updated: September 19, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2033
  Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)